S phingosine-1-phosphate (S1P) is a bioactive metabolite of the sphingomyelin pathway that plays key roles in vascular development and homeostasis.
S1P 1 signaling stabilizes endothelial adherens junctions and promotes blood flow, whereas smooth muscle cell S1P 2 and S1P 3 promote vascular contraction and, thereby, regulate vascular tone. 5, [7] [8] [9] [10] Circulating S1P plays a key role in the activation of vascular receptors because lack of blood-borne S1P impairs vascular development, perturbs homeostatic maintenance of vascular integrity, and dramatically increases anaphylaxis mortality. 11, 12 Plasma S1P, presumed to be saturating for endothelial lumenal S1P receptors, is provided by several types of cells and carried on different chaperones. 1, 13 Although this may argue that redundancy between vascular sources of S1P secures essential functions of S1P signaling, several recent studies suggest nonredundant roles for both erythrocyte-and platelet-derived S1P, as well as bias in S1P delivery to plasma chaperones and in chaperone-dependent S1P signaling. 11, [14] [15] [16] [17] Considering the critical roles of S1P signaling in vascular development and homeostasis, it is important to define the relative and potentially unique contribution of the main sources of circulating S1P to the activation of different vascular receptors and the potential effects of S1P source exhaustion or depletion on vascular function. Notably, sources of circulating S1P can be selectively depleted in disease states; high-density lipoprotein and platelet pools have been shown to be exhausted in severe sepsis and myocardial infarction, respectively. [18] [19] [20] If these sources are indeed nonredundant, such exhaustion could have profound effects on vascular function. Depending on the level of redundancy, anemia, thrombocytopenia, or inhibition of tissue-specific S1P metabolism, transporters or release mechanisms could also result in S1P deficiency-associated vascular dysfunction.
Plasma S1P is provided by erythrocytes and endothelial cells (which also provide lymph S1P) and is carried by highdensity lipoprotein--and low-density lipoprotein-associated apolipoprotein M, as well as by albumin ( Figure 1A ). 1, [21] [22] [23] S1P is actively removed from interstitial fluids, generating a gradient that is required for lymphocyte egress to blood and lymph. 25 Two mammalian sphingosine kinase (Sphk) isoforms (1 and 2) are partly redundant for S1P generation. 26 Platelets and erythrocytes do not efficiently degrade S1P and, therefore, have a high S1P synthetic capacity 23, [27] [28] [29] ( Figure 1A ). Embryonic bleeding and death associated with erythrocyte S1P deficiency argues that erythrocyte-derived S1P may play a unique role in endothelial S1P 1 activation. 11 This and the observation that platelets do not contribute to plasma S1P 21, 23 question the functional importance of platelet-derived S1P in homeostasis. Yet a doubling of S1P levels in serum relative to plasma suggests that platelet activation has the potential to substantially augment local S1P concentrations, 27 potentially engaging receptors that are not saturated by plasma S1P, for example, on vascular smooth muscle cells, or changing the bias or balance of receptor activation. 30, 31 Intriguingly, in this regard, a recent study argued a key role for platelet S1P release and paracrine activation of endothelial S1P 1 after activation of platelet immunoreceptor tyrosine-based activation motif-coupled receptors. 14 In a model of immunization-induced bleeding in draining lymph nodes, individual platelets were shown to gain subendothelial access at high endothelial venules. In the absence of the platelet immunoreceptor tyrosine-based activation motif receptor C-type lectin-like receptor 2 (CLEC-2), reticular epithelial podoplanin, or platelet S1P, lymph node bleeding was observed. Platelet immunoreceptor tyrosine-based activation motif-coupled receptors maintain vascular integrity during vascular development and inflammation and mediate blood/lymph separation [32] [33] [34] ; the role for platelet-derived S1P as a downstream mediator in these settings remains to be explored. Another recent study demonstrated an important cell-autonomous role for S1P in platelet activation and thrombosis, arguing that platelet S1P is relevant for platelet S1P 1 activation even in the presence of erythrocyte-derived plasma S1P. 15 Importantly, however, selective ablation of S1P production in megakaryocytes was not used to confirm a role of platelet S1P in either study. S1P release by platelets appears to be largely dependent on thromboxane formation and sensitive to nonselective cyclooxygenase inhibitors, such as aspirin (acetylsalisylic acid) and ibuprofen. 35 Platelet S1P release may, thus, be inhibited by over-the-counter nonsteroidal anti-inflammatory drugs, highlighting the importance of revealing its functions. While the role for S1P production in endothelium has not been directly tested, Sphk1 is dynamically regulated by both G protein-coupled receptor and tyrosine kinase receptors and has been proposed to be important for barrier protective signaling in endothelium by S1P 1 transactivation. 36, 37 To explore roles for platelet-derived S1P and redundancy between circulating and resident S1P sources in vascular development and homeostasis, we generated mice with isolated or combined tissue-specific deficiency of Sphks 1 and 2 in megakaryocytes/platelets, erythrocytes, endothelial cells, and smooth muscle cells, and compared effects of S1P source deficiency to effects of thrombocytopenia or deficiency in vascular S1P receptors. Using washed platelets from platelet S1P-deficient mice, we observed autocrine roles for S1P in platelet activation and spreading and a key paracrine role for S1P in modulation of endothelial barrier function by platelets. Yet experiments comparing the impact of platelet S1P deficiency to that of other S1P source deficiencies or thrombocytopenia during developmental-, physical-, inflammatory-, and irradiation-induced vascular challenge all argued that roles observed for platelet S1P ex vivo were compensated for by other mechanisms and S1P sources in vivo. Accordingly, experiments designed to test essential roles proposed for platelet-derived S1P in thrombosis and lymph node vascular integrity and erythrocyte-derived S1P in where the other copy was deleted in all cells (f/−:f/−) or by tissue-specific recombination of 2 loxP flanked copies of one kinase gene in a context where both copies of the other kinase gene were deleted in all cells (f/f:−/−). D, Overview of Cre alleles, their target cells, and effect of Sphk deletion on S1P levels in platelets, erythrocytes, and plasma under homeostasis as determined above or published elsewhere. 11, 23, 24 Note that erythrocytes and platelets make near exclusive use of Sphk1 and Sphk2, respectively, for S1P production and that while relevant target cells of Mx1Cre (erythrocytes and lymphatic endothelial cells) continuously provide S1P to plasma, platelets only release their S1P content on activation and, thus, contribute to serum but not plasma S1P. Blood endothelium does not contribute measurably to plasma S1P, but may still constitute a relevant source for activation of vascular receptors. ApoM indicates apolipoprotein M; EC, endothelial cell; eNOS, endothelial nitric oxide synthase; Epor, erythropoietin receptor; L-Arg, L-arginine; Mx1, myxovirus resistance-1; ND, not determined; NO, nitric oxide; Pdgfb, platelet-derived growth factor beta; Pf4, platelet factor 4; Rac, Rac GTPase; ROCK, Rho-associated protein kinase; SM22, smooth muscle protein 22; and Sphk2, sphingosine kinase 2.
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vascular development with targeted genetic approaches failed to confirm the need for any single source when competing sources were left intact. On the other hand, we observed that plasma S1P is depleted during anaphylactic shock, rendering S1P delivery by both platelets and erythrocytes essential for recovery.
Methods
Mice
Genetically mutant mice used in this study were of mixed C57BL/6J:129SVJ background and compared with age-and sexmatched littermate controls. Wild-type (WT) C57BL/6J mice were purchased from Charles River or Janvier laboratories. Each point in dot-plots represents a sample from one mouse with the exception of plasma S1P measurements for which plasma from several mice of the same genotype were in some cases pooled. 23 Mice deficient in S1P production in megakaryocytes and platelets (Sphk1 :Pf4Cre + ) were generated using a Pf4Cre allele.
39 S1pr1 floxed, S1pr2, and S1pr3 knockout and PdgfbiCreERT alleles have been described. [40] [41] [42] [43] Endothelial-specific deletion of S1pr1 was achieved by oral administration of 20 μg tamoxifen to S1pr1 f/f :PdgfbiCreERT neonates thrice between p1 and p5.
Endothelial Barrier Function
Transendothelial electric resistance (TEER) was assessed using electric cell-substrate impedance sensing (Applied Biophysics) at 4000 Hz. 44 Human umbilical vein endothelial cells (PromoCell) were plated at 10 5 cells/fibronectin coated 8W10E(+) well. The day after, cells were equilibrated (2 hours) in serum-free endothelial cell basal medium (PromoCell) before establishing baseline resistance (1 hour). 10 7 washed platelets were then added, followed by a protease-activated receptor-4-activating peptide (500 μM). Where indicated, endothelial cells were pretreated with the S1P 1 antagonist W146 (1 μM) or vehicle control before the addition of platelets.
Inflammation-Associated Bleeding
Models of inflammation-associated bleeding have been described elsewhere. 14, 34, 45 Briefly, reverse passive Arthus reaction was elicited subcutaneously with anti-BSA IgG (60 μg) immediately followed by BSA (50 μg/g) intravenously. Mice were euthanized 4 hours later, and biopsies of control and inflamed skin were photographed for blinded scoring of petechiae, harvested, weighed, homogenized, and sonicated in cold phosphate-buffered saline for measurement of hemoglobin content and myeloperoxidase activity. Lung inflammation was induced by intranasal inoculation with 25 μg Pseudomonas aeruginosa lipopolysaccharide. Six hours later, bronchoalveolar lavage was performed and hemoglobin and blood cell content quantified. Immunization was induced by injection of 20 μL of an emulsion of complete Freunds adjuvant/Ovalbumin phosphate-buffered saline in the right hock.
14 One week later, mice were anesthetized and transcardially perfused to remove intravascular blood, and lymph node bleeding was assessed.
Study Approval
Experimental procedures were approved by the animal ethics committee of the Paris Descartes University and the French Ministry of Research and Higher Education (03686.02; 02822.02; 03651.02).
Statistical Analyses
Statistical significance of differences in survival outcome was assessed with the Gehan-Breslow-Wilcoxon test; differences in sphingolipid levels, calcium signaling, platelet aggregation and adhesion, Evans Blue leak, myeloperoxidase, leukocyte counts, bleeding, thrombosis, hemoglobin, edema, hematocrits with the Mann-Whitney test; and P-selectin exposure, TEER, paw swelling, cardiac and blood flow parameters by 2-way analysis of variance. Cross-comparisons between experimental groups in Figure 6E were performed by Kruskal-Wallis test followed by Dunn's multiple comparison test. *P<0.05; **P<0 .01;**P<0.0001; ****P<0.00001; ns, not significant; n, number of animals included.
Additional details concerning the mouse lines and materials, as well as additional methods, online figures, and figure legends can be found in the Online Data Supplement.
Results
Effects of Global and Tissue-Restricted Sphk Deficiencies on Circulating Pools of S1P
We generated mice with compound deficiency of Sphk1 and Sphk2 in megakaryocytes/platelets (platelet S1Pless), erythrocytes, endothelial cells, smooth muscle cells, or all cells providing S1P to plasma (plasma S1Pless) by crossing Sphk1 and Sphk2 conditional (floxed, f) and global (−) knockout alleles 23 to Cre recombinase genes driven by platelet factor 4 (Pf4Cre), 39 erythropoietin receptor (Epor-Cre), 11 platelet-derived growth factor beta (PdgfbiCreERT2), 40 smooth muscle protein 22-alpha (SM22-Cre), and Myxovirus resistance-1 (Mx1Cre) 23 promoters, respectively. S1P source mutants were first generated with 1 floxed allele and 1 knockout allele for each kinase, with controls differing from knockouts only by the presence of the Cre allele (Sphk1 f/− :2 f/− :Cre +/− ), although variants where the gene for one kinase was deleted in a tissue-specific manner in a context where the gene for the other kinase was absent in all cells (eg, Sphk1 f/f :2 −/− :Cre +/− ) were also generated for comparison with published reports. Plasma S1Pless mice and the erythrocyte S1Pless mice have already been described, and they have <10% of normal plasma and <2% of normal erythrocyte S1P, respectively. 11, 23 S1P levels in lysed platelets and activation-induced S1P release from washed platelets from platelet S1Pless mice (Sphk1 f/− :2 f/− :Pf4Cre + ) were both below detection limits for most donors, with a matching reduction in serum, but not plasma ( Figure 1B) . No significant change was observed in sphingosine levels in plasma, serum, or platelet supernatants (Online Figure I) . Intriguingly, Sphk1 and Sphk2 were almost exclusively required for erythrocyte and platelet S1P production, respectively ( Figure 1C) . As a consequence, both classical plasma S1Pless mice, 12, 14, 23 which are rendered profoundly plasma S1P deficient by postnatal deletion of Sphk1 in hematopoietic cells and lymphatic endothelial cells in a Sphk2
and their Cre − controls, were devoid of platelet S1P ( Figure 1C ). Deletion of Sphk1 and Sphk2 in blood endothelium had no impact on plasma S1P levels even in the context of compound deletion in hematopoietic cells and lymphatic endothelium ( Figure 1C) . Collectively, these observations confirm that erythrocytes and lymphatic endothelial cells are the main sources of plasma S1P under homeostasis (without contribution from platelets or blood endothelium), 23 suggest cell-selective use of Sphks that has important consequences for the interpretation of reports of nonredundant roles of S1P sources, and argue that megakaryocyte deletion of Sphks yields platelets that remain S1Pless and do not scavenge S1P from plasma ( Figure 1D ). 
Sphk Deficiency Impairs Aggregation and Spreading of Washed Platelets
Because S1P has been reported to induce platelet shape change, 27 we evaluated the function of S1Pless platelets. Maximal and cumulative increases in cytosolic-free calcium in response to α-thrombin were indistinguishable between washed S1Pless and littermate control platelets ( Figure 2A ). P-selectin exposure in response to a peptide agonist for the thrombin receptor protease-activated receptor-4 was found to be grossly normal, although delayed in platelets from some platelet S1Pless donors ( Figure 2B) . A delayed response was seen in aggregation to collagen, while ADP-induced aggregation was also impaired at later times ( Figure 2C ). Platelet spreading (lamellipodia formation) on fibrinogen was reduced with platelet S1P deficiency ( Figure 2D ). These observations suggest an autocrine role for platelet S1P release in platelet activation and, thus, a potential role for S1P in hemostasis and thrombosis and are consistent with recent observations by Urtz et al.
15
Platelets Promote Endothelial Barrier Function Ex Vivo by Release of S1P
We next addressed the importance of S1P release for the capacity of platelets to promote TEER, which reflects on endothelial barrier function. We observed a robust increase in TEER when washed platelets from WT mice were added to human umbilical vein endothelial cell grown to confluence on fibronectin-coated microelectrodes ( Figure 3A ). When the platelets were activated with protease-activated receptor-4-agonist peptide, we observed a rapid further increase in TEER that was succeeded by a decrease and subsequent recovery ( Figure 3A) . The initial increase in barrier function observed without deliberate activation of the platelets was blunted with the S1P 1 antagonist W146 and may reflect constitutive release of S1P from the plasma membrane. 46 W146 also reduced basal resistance, consistent with tonic barrierpromoting S1P signaling in endothelium. 9, 12 S1Pless platelets were strongly impaired in their ability to promote barrier function ( Figure 3B ), as were platelets from Sphk2 −/− donors, confirming a dominant role for Sphk2 in S1P production ( Figure 3C and 3D) . Unlike mass spectrometry ( Figure 1B) , this assay uncovered a minor but significant contribution of Sphk1 to platelet S1P release (Sphk1 Figure 3D , left panel). These results confirm that S1P is a key endothelial barrier-promoting factor released by platelets. Because our ex vivo observations were consistent with a proposed paracrine role of S1P downstream of platelet CLEC-2, 14 we next addressed whether platelet S1P deficiency was associated with developmental defects reminiscent of deficiency in CLEC-2 signaling. 32 Blood/lymph mixing at E14.5 after PF4Cre-mediated deletion of a LoxP-flanked CLEC-2 allele suggests that PF4Cre mediates efficient excision by this time. 33 However, although thrombocytopenic Nf-e2 −/− embryos 47 isolated in parallel exhibited both brain bleeds and blood in lymphatic structures as reported for CLEC-2-deficient embryos, neither phenotype was observed with platelet S1P deficiency at E12.5 or E14.5 ( Figure 4A ). 48 Erythrocyte-derived S1P was recently reported to be essential for vascular development 11 and is likely to compensate for developmental platelet S1P deficiency. Considering that platelets have strong S1P-mediated paracrine actions on cultured endothelium (Figure 3 ) and appear in circulation 
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around E10.5, 49 it is surprising that platelet S1P cannot also compensate for a lack of erythrocyte-derived S1P. Notably, bleeding and death reported for erythrocyte S1P deficiency were only observed when Sphk1 was deleted in erythrocytes in embryos that were also Sphk2 Figure 4A ), arguing against a nonredundant role for erythrocytes in S1P provision. Embryonic bleeding was also not observed in Sphk1 −/− :Sp hk2 f/− Pf4Cre + embryos ( Figure 4A ), predicted to lack both erythrocyte and platelet S1P (Figure 1 ), suggesting that endothelium-derived S1P may also be sufficient to support development.
Birthing trauma also induced cerebral bleeding at a frequency that was enhanced with Nf-e2 −/− deficiency ( Figure 4B ). Although neonatal brain bleeding was observed also in Sphkdeficient mice, it did not increase with platelet or platelet-and erythrocyte-S1P deficiency ( Figure 4B ).
Collectively, these observations argue that although erythrocytes may be sufficient, 11 no single cellular source is essential for providing bioactive S1P to support S1P 1 signaling during embryonic development.
Redundancy of S1P Sources in Vascular Integrity, Hemostasis, and Thrombosis in Adult Mice
As previously reported, lack of Sphk1 and Sphk2 in all cells that provide S1P to plasma was associated with constitutive vascular leak to lung in adult mice ( Figure 5A ). 12 This was phenocopied by postnatal deletion of S1pr1 in endothelial cells (S1pr1 f/f :PdgfbiCre + ) and, thus, reflected lack of endothelial S1P 1 signaling ( Figure 5A ). By contrast, we did not observe significant vascular leak with isolated deficiency in S1P production in platelets, erythrocytes, or endothelial cells ( Figure 5A ), arguing source redundancy also in adult mice, under homeostasis. As platelet S1P is likely to be engaged only during vascular inflammation or injury, we explored the role for this source further. Release of platelet S1P after CLEC-2 activation might suggest a role for platelet S1P in supporting vascular integrity during inflammation 34 ; yet, platelet S1P deficiency did not enhance histamine-induced paw edema ( Figure 5B ) as was observed for plasma S1P deficiency, 12 and neither platelet-(Sphk1 Figure 5C ) or skin ( Figure 5D ) inflammation even if platelet depletion did. Platelet S1P deficiency also did not influence neutrophil recruitment in these models ( Figure 5C and 5D). 50 Besides paracrine action on endothelium, our ex vivo observations supported a possible cell autonomous role for S1P in platelet activation, consistent with Urtz et al. 15 We, therefore, next addressed if platelet S1P deficiency impaired hemostasis in adult mice and if protection from thrombosis reported in Sphk2 global knockouts resulted from S1P deficiency in platelets. 15 However, we found no effect of platelet S1P deficiency on tail-bleeding times nor on time to ferric chloride-induced occlusion of the carotid artery ( Figure 5E and 5F). To address whether platelet-derived S1P might prevent subtle vascular injury, we then transplanted irradiated WT mice with Nf-e2 −/− or platelet S1Pless hematopoietic progenitor cells. Mice transplanted with Nf-e2 −/− fetal liver cells uniformly displayed cerebral hemorrhage 10 to 13 days after irradiation, which was not observed in controls ( Figure  5G ). However, bleeding was not observed after transplantation of bone marrow (BM)-derived cells from even profoundly platelet S1Pless Sphk1 f/f :Sphk2 −/− :Pf4Cre + donors ( Figure 5G ). These results suggest that despite autocrine and paracrine actions observed ex vivo (Figures 2 and 3 ), other S1P sources and other mechanisms will in most cases render platelet-derived S1P redundant for platelet activation and vascular integrity in vivo.
Platelets and Erythrocytes Provide Redundant Sources of Lymph Node-Protective S1P After Immunization
Surprised that the essential role reported for platelet S1P downstream of CLEC-2 signaling after immunization 14 did not extend to other settings where CLEC-2 signaling has been implicated, we addressed whether platelet S1P deficiency indeed sensitizes to lymph node bleeding. Supporting protective roles for both platelets and S1P, we observed blood in draining lymph nodes of both plateletdepleted and plasma S1Pless mice (Sphk1 f/f :2 −/− :Mx1Cre + ) 1 week after immunization in the right hock ( Figures 6A-6C) . 51 Greatly reduced bleeding in chimeric Sphk1 f/f :2 −/− :Mx 1Cre + mice transplanted with WT BM also supported a role for a circulating S1P source ( Figure 6C ). However, platelet S1P was not essential because removal of even the minor Sphk1-derived S1P in Sphk2 −/− platelets did not enhance bleeding (Sphk1 f/f :2 −/− :Pf4Cre + ; Figure 6C ). Accordingly, erythrocyte-derived S1P was sufficient to prevent bleeding because transfusion of washed, packed erythrocytes on days 4 and 6 after immunization prevented bleeding in Sphk1 f/f :2 −/− :Mx1Cre + mice ( Figure 6C ). Erythrocytes from (Figures 6D and 6E ). Although these observations support a role for circulating S1P in preserving lymph node integrity after immunization, they argue against a nonredundant role for the platelet source. Figure 5 . Effects of sphingosine-1-phosphate (S1P) deficiencies on vascular integrity, hemostasis, thrombosis, and leukocyte recruitment in adult mice. A, Constitutive Evans Blue leak to lung in mice-deficient in S1P sources or the endothelial S1P 1 receptor. B, Histamine (60 μg)-induced paw swelling normalized for increase in paw diameter after vehicle injection in the contralateral paw. C, Hemoglobin and myeloid cells in bronchoalveolar lavage 6 hours after intranasal inoculation of lipopolysaccharide (LPS; 25 μg). Platelet depletion triggered bleeding and reduced leukocyte accumulation in lung, whereas S1P deficiency did not affect either parameter. D, Hemoglobin, bleeding score, myeloperoxidase (MPO) activity, and weight of skin biopsies 4 hours after semisimultaneous subcutaneous injection of anti-BSA and intravenous injection of BSA (left). Bleeding, MPO activity, and weight were all increased in reverse passive Arthus reaction (rpA) biopsies relative to control independent of genotype. Representative images (right) show occasional mild petechiae at sites injected with anti-BSA antibody in Sphk1 f/− :2 f/− mice independent of Pf4Cre status. E and F, Bleeding times after removal of the distal 3 mm of the tail (E) and time to arterial occlusion after 4 minutes exposure of the carotid artery to a FeCl 3 (15%) swab (F). Platelet S1P deficiency did not influence either end point, nor hemoglobin content in collected blood in E or in embolization in F. G, C57BL/6 wild-type mice were transplanted with platelet S1P-deficient bone marrow (BM) or Nf-e2 −/− fetal liver (FL) cells the day after Cesium 137 irradiation. Ten or 13 days (d) later, brains were removed after transcardial perfusion. Left, Representative brains 13 days after transplantation; right, summary. Platelet-but not platelet S1P deficiency resulted in brain bleeding after irradiation. 
Platelet and Erythrocyte Sources of S1P Are Both Required for Recovery From Anaphylactic Shock
Compound erythrocyte, platelet, and lymphatic endothelial S1P deficiency in plasma S1Pless mice leads to constitutive vascular leak and sensitizes mice to vascular leak and death from passive systemic anaphylaxis induced with immune complexes or with platelet-activating factor (PAF), a key mediator of anaphylactic shock in mice. 12, 52 Even if PAF does not directly activate mouse platelets, 53 intravital microscopy revealed an enhancement of transient and stable interactions between platelets and the endothelium of mesenteric vessels after PAF challenge ( Figure 7A and Online Videos I and II). A halving in platelet S1P content 40 minutes after challenge suggested that they also release S1P in this context ( Figure 7B ). Strikingly, however, despite engagement of the platelet pool of S1P and its continued production by erythrocytes, plasma levels were reduced by >80% on average (85±47 versus 451±52 nmol/L; P>0.0001; Figure 7B ). Depletion of plasma S1P to levels at or below the threshold needed to saturate S1P receptors hinted at greater dependence on circulating S1P sources in this context. Accordingly, chimeric WT mice with Sphk1 Figure 7C ) even if nonhematopoietic sources provide sufficient S1P to sustain lymphocyte trafficking and vascular integrity in these mice under homeostatic conditions (Online Figure IIA) . 23 Arguing a necessary role for both circulating cellular sources of S1P, sensitization to PAF challenge was also observed in platelet S1P-deficient mice without exacerbation of vascular leak, conferred by transplantation of BM-derived cells from these mice, and observed in mice with isolated lack of erythrocyte-derived S1P ( Figure 7C ; Online Figure IIB) . By contrast, impaired S1P production in blood endothelium (Sphk1 Figure 7D ). Addressing if inhibition of S1P release from platelets with nonsteroidal anti-inflammatory drugs 35 would influence recovery from anaphylaxis, we observed that pretreatment with aspirin or ibuprofen mirrored platelet S1P deficiency in exacerbation of PAF-induced mortality ( Figure 7E ; Online Figure III) . In stark contrast, aspirin treatment was protective in mice that lack platelet S1P ( Figure   Figure 6 . Platelets and sphingosine-1-phosphate (S1P), but not platelet-derived S1P, are essential for lymph node hemostasis after immunization. A-E, Mice were immunized in the right hock, and draining and control lymph nodes isolated 1 week later for gross assessment of bleeding. Bleeding on the efferent surface of the right popliteal lymph node was scored in a blinded manner according to the scale shown in A. In B, anti-GPIbα antibodies were administered to C57BL/6 males the day (Continued ) 7E). Suggesting a dependence on S1P dose rather than unique roles for S1P sources, the requirement for platelet S1P was overcome in mice globally deficient in Sphk2, which paradoxically have high plasma S1P levels and were protected from mortality ( Figure 7F ). 54 Unlike platelet deficiency and consistent with aspirin-treated platelets maintaining the capacity to prevent inflammation-associated bleeding, 34 no overt bleeding was observed in aspirin-treated animals after PAF challenge (0/10 animals analyzed). Thus, anaphylactic shock is associated with rapid depletion of plasma S1P, which renders S1P contribution by both platelet and erythrocyte sources necessary for recovery and supraphysiological plasma S1P levels as observed in Sphk2 −/− mice protective.
Circulating S1P Promotes Anaphylaxis Survival by Maintaining Vascular Tone
S1P has been suggested to provide protection in mouse models of anaphylaxis by promoting vascular integrity, vascular tone, and glomerular filtration. 12,54-57 Although we originally focused on the role of S1P 1 in protecting vascular integrity during systemic anaphylaxis, 12 Olivera et al later argued the importance of S1P 2 signaling and vascular tone regulation. 55 In support of Olivera et al, endothelial-selective S1P 1 deficiency had no effect on PAF survival ( Figure 8A ), despite inducing constitutive vascular leak ( Figure 5A ). To address if increased lethality associated with S1P deficiency was instead of hemodynamic origin and S1P 2 -dependent, we monitored blood pressure and heart rate after PAF injection. PAF induced a rapid drop in blood pressure independent of genotype, which was followed by continued decline and death in plasma S1Pless and S1pr2 −/− mice, contrasting gradual recovery in most controls ( Figure 8B ). In a likely last attempt to maintain blood pressure, death was preceded by transient tachycardia in most S1P signaling-deficient animals ( Figure 8B ). Although this supports a role for S1P in maintaining vascular tone, genotype-dependent differences were unremarkable relative to differences in survival and did not reveal effects of isolated platelet or erythrocyte S1P deficiency (Online Figure IV) . Profound anesthesia, temperature control, and compensatory pathways engaged to maintain pressure may have masked the contribution of S1P signaling to vascular tone in these experiments. We, therefore, next assessed renal artery and basilar trunk blood flow velocities, left ventricular systolic function, and cardiac output before and 30 minutes after PAF administration under mild isoflurane anesthesia by noninvasive echocardiography and ultrasound pulsed Doppler analysis ( Figure 8C ; Online Figure  V) . With these techniques, we observed a striking decrease in systolic and diastolic left ventricular diameters, cardiac output, and organ perfusion in plasma S1Pless mice, suggesting exaggeration of circulatory shock with distributive and hypovolemic components, leading to a drop in venous return to the heart and, thus, in cardiac output ( Figure 8C) . [58] [59] [60] A similar phenotype was observed with platelet S1P deficiency and in S1P 2 -deficient mice ( Figure 8C and Online Figure  V) . 41 Although S1P 2 deficiency was associated with significantly increased mortality in these experiments ( Figure 8D ), sensitization was not as strong as for plasma S1P deficiency. Accordingly, protective effects of Sphk2 deficiency ( Figure  7F ), presumed to reflect high plasma S1P concentrations, persisted in an S1pr2 −/− background ( Figure 8E ). S1pr2 −/− sensitization was not exacerbated by compound deficiency of S1P 3 , 41,42 the second smooth muscle contractile S1P receptor ( Figure 8F ). This could argue that lack of S1P 1 signaling and exacerbated vascular leak nevertheless contributes to poor venous return and more severe circulatory shock in plasma S1Pless mice ( Figure 8C ; Online Figure V) . 12 Collectively, and consistent with Olivera et al, 55 these observations suggest that although S1P promotes both vascular integrity through S1P 1 and vascular tone through S1P 2 , the latter dominates but does not fully account for the survival benefit of S1P signaling in anaphylaxis.
Discussion
We have explored functional roles for platelet-derived S1P in vitro and compared effects of platelet S1P deficiency to thrombocytopenia and to erythrocyte, endothelial, smooth muscle, and plasma S1P deficiency on vascular development and homeostasis in vivo. Deletion of Sphk1 and Sphk2 in mouse megakaryocytes abrogated S1P release from platelets without affecting plasma S1P levels, supporting the notion that platelets do not contribute substantially to plasma S1P under homeostasis. 21 ,23 S1P deficiency partially impaired platelet aggregation and spreading and nearly eliminated the ability of platelets to promote endothelial barrier function in vitro. However, it did not result in bleeding or vascular fragility or protect from arterial thrombosis in vivo. Despite its importance in isolated systems, platelet S1P, thus, seems to be redundant for hemostasis, thrombosis, and vascular integrity when other S1P sources or other protective mechanisms are intact. Although these observations contrast essential roles recently reported for platelet-as well as erythrocyte-derived S1P for S1P 1 activation during vascular development, 11 immunization, 14 and thrombosis, 15 such requirements were not observed in this study when S1P deficiency was induced specifically in the relevant cells in a genetic context where major competing sources were left intact. Contrasting the source redundancy Figure 7 Continued. respectively. Insets show higher-magnification views of squared regions. Images are representative of observations made in 6 mice. B, S1P concentrations in platelets, erythrocytes, and plasma of C57BL/6J wild-type mice 40 minutes after PAF (4 μg/ kg) or vehicle challenge. Note S1P depletion from platelets and plasma, but not erythrocytes. C-F, Mice were injected with PAF at indicated concentrations and survival monitored for 60 minutes. Note that S1P deficiency in circulating cells; in chimeric wild-type (WT) mice with sphingosine kinase (Sphk) deficiency in all bone marrow (BM) cells (Sphk1 Figure 8 . Sphingosine-1-phosphate (S1P) promotes recovery from anaphylactic shock by S1P 2 -mediated enhancement of vascular tone. A, Mice selectively lacking S1P 1 in blood endothelium (S1pr1 f/f :PdgfbiCre + ) were challenged with platelet-activating factor (PAF) and survival monitored for 60 minutes. B, Plasma S1Pless (Sphk1 f/− :2 f/− :Mx1Cre + ), S1P 2 deficient mice (S1pr2 −/− ), and littermate controls were challenged with PAF (2 μg/kg) under pentobarbital anesthesia, and blood pressure and heart rate were monitored for 60 minutes and normalized to prestimulation values. Asterisk indicates death of an animal. C, Plasma S1Pless (Sphk1 f/ f :2 −/− :Mx1Cre + ), chimeric wild-type (WT) mice with megakaryocyte sphingosine kinase (Sphk)1-and 2-deficient bone marrow (BM; Sphk1 f/− :2 f/− :Pf4Cre + ), S1P 2 -deficient mice (S1pr2 −/− ), and respective controls were challenged with PAF (4 μg/kg) and left ventricular systolic function and blood flow velocities in the right renal artery and basilar trunk determined 30 minutes later by echocardiography and ultrasound pulsed Doppler analysis under light (0.5%) isoflurane anesthesia. Left ventricular internal diameter in diastole (LVIDd), cardiac output, right renal artery, and basilar trunk mean blood flow velocities before and after PAF challenge. D-F, Mice globally deficient in S1P 2 either alone (S1pr2 −/− ; D) or in conjunction with Sphk2 (S1pr2 −/ :Sphk2 −/− ; E) or S1P 3 (S1pr2 −/− S1pr3 −/− ; F) and littermate controls were challenged with PAF at indicated concentrations and survival monitored for 60 minutes. Note that only S1P 2 deficiency sensitizes to PAF, independent of S1P 3 , although residual protection by Sphk2 deficiency in a S1pr2 −/− background suggests the involvement of second receptor. 
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observed in vascular development, homeostasis, and local inflammation, rapid and profound depletion of the plasma pool rendered S1P delivery by both platelets and erythrocytes essential for recovery in a model of systemic anaphylaxis where S1P 2 signaling maintains vascular tone. A contribution of bioactive S1P from the vessel wall was revealed only in the absence of both circulating sources. Aspirin, which impairs S1P release from platelets, 35 sensitized to anaphylaxis mortality in an S1P-dependent manner.
Because cells of nonhematopoietic origin contribute enough S1P to sustain plasma S1P levels well above the K d for S1P 1 binding, 21, 23, 61 it is surprising that the absence of erythrocyte and, especially, platelet S1P would lead to a deficit in activation of S1P 1 on cells in contact with plasma as has recently been reported. 14, 15, 62 Our observations suggest that the importance of single S1P sources was exaggerated by the genetic context in which these studies were performed. Although we confirm S1P dependence in the same models, we fail to confirm necessary roles for plateletor erythrocyte-derived S1P when using more specific genetic tools. When S1P release from platelets was proposed to provide a critical barrier-protective signal to S1P 1 on high endothelial venules after platelet activation by CLEC-2/ podoplanin, this was tested using mice that lack Sphk1 in cells that provide S1P to plasma and Sphk2 in all cells. 14, 23 Our results argue that also the Sphk2 −/− littermate controls used were devoid of platelet S1P and that the Cre-dependent differences observed, therefore, could not have reflected on a role for the platelet S1P source. Moreover, although we also observed bleeding with plasma S1P deficiency that could be rescued by transplantation of WT BM-derived cells, this was not replicated by megakaryocyte-specific deletion and could be reversed by transfusion of erythrocytes. Thus, although platelet S1P may be sufficient to prevent lymph node bleeding in this context, it is not necessary. The critical role of erythrocyte-derived S1P in engaging S1P 1 to coordinate vascular developmental was also demonstrated in an Sphk2 −/− background 11 and, thus, did not address the potential contribution of Sphk2-derived S1P from platelets and possibly endothelial cells. When we tested this directly by generating embryos lacking S1P in erythrocytes without impairing competing sources, development proceeded normally. Finally, when platelet-derived S1P was shown to be important for autocrine activation of platelet S1P 1 in thrombosis, this was performed with mice deficient in Sphk2 in all cells, 15 which also display thrombocytopenia and supraphysiological plasma S1P levels. 54, 63 Although we also observed functional defects in S1P-deficient platelets ex vivo, we did not confirm protection against ferric chloride-induced carotid thrombosis when Sphk2 was selectively deleted in megakaryocytes/platelets. Thus, although S1P coordinates vascular development and integrity and possibly platelet activation and spreading, no single cellular source of S1P seems to be essential for these processes. This is not surprising, as depletion of any single source should not reduce plasma S1P to levels below S1P receptor saturation. 21, 23, 61 Because we also did not observe spontaneous vascular leak with compound Sphk1 and Sphk2 deficiency in endothelium, these data underscore the importance of plasma S1P, which is maintained by several redundant sources, to maintain vascular integrity during embryogenesis and postnatal homeostasis.
Considering that we did not find support for a barrierprotective role for S1P downstream of platelet CLEC-2 in lymph nodes, it is perhaps not surprising that we also did not observe blood/lymph mixing phenotypes or sensitization to local inflammation-induced hemorrhage in platelet S1Pless mice. These experiments also did not reveal a role for plateletderived S1P in modulating neutrophil recruitment or neutrophil-mediated damage. 50 If S1P accounts for most endothelial barrier-protective capacity of platelets in vivo as we observe ex vivo, this may favor models in which platelets protect against inflammation-induced hemorrhage by S1P-independent suppression of leukocyte-mediated injury or by physical prevention of erythrocyte escape 64 rather than by paracrine actions on the endothelium.
14 Our results do not support a key role for S1P as a platelet-derived mediator in any of these models and suggest that only profound S1P deficiency is associated with hemorrhage and only in unique situations, such as during vascular development and tissue remodeling.
The surprising observation that plasma S1P was profoundly depleted in a model of anaphylactic shock argued that the amount of S1P available for receptor activation can drop below saturating levels during systemic inflammation, rendering the contribution of all residual cellular sources of S1P essential. Although the mechanisms of S1P depletion remain to be addressed, nonredundant roles for both platelet-and erythrocyte-derived S1P identified in this model contrasted models of local inflammation and suggested a contribution from both circulating sources, independent of any qualitative differences. Protection in mice with supraphysiological homeostatic plasma S1P levels argued that these sources were, nevertheless, not adequate to sustain S1P receptor activation. This is consistent with reports that S1P infusion can promote recovery from histamine-induced shock. 55 Exacerbated hypotension, loss of vascular tone, and poor blood return to the heart observed in mice lacking S1P argued that S1P could contribute to both distributive and hypovolemic components of shock in the PAF model. 58 Suggesting a dominant role in maintaining vascular tone, 55 sensitization with platelet S1P deficiency was not associated with enhanced vascular leak or bleeding, and endothelial deficiency of S1P 1 did not affect survival, despite inducing constitutive vascular leak to lung. By contrast, deficiency of S1P 2 , which promotes smooth muscle contractility and myogenic tone, was associated with severe vasoplegia and increased lethality. A persistent survival benefit afforded by Sphk2 deficiency in an S1pr2 −/− background may, nevertheless, suggest a contribution of S1P 1 or another receptor to S1P protection. 8 A protective role for platelet-derived S1P in anaphylaxis begs the question of whether antithrombotic or anti-inflammatory therapies impair platelet S1P release and, thus, may influence recovery from circulatory shock. Thromboxane synthesis plays an important role in platelet S1P release, evidenced in part by the inhibitory effect of nonsteroidal anti-inflammatory drugs. 35 This predicted that nonsteroidal anti-inflammatory drugs might impair recovery from PAF-induced shock similar to platelet S1P deficiency, which is indeed what we observed with both aspirin and ibuprofen. Remarkably, the effect of aspirin was inversed in mice lacking platelet S1P. It remains to be determined if the protective role of platelet S1P extends to other inflammatory conditions known to be aggravated by thrombocytopenia.
65,66
In conclusion, our observations with tissue-specific ablation of S1P production in mice suggest that provision of S1P to plasma from multiple cellular sources normally secures sufficient S1P receptor activation to sustain vascular development, vascular integrity and tone, and possibly hemostasis through platelet activation and spreading. However, systemic inflammation may lead to rapid depletion of plasma S1P, rendering the contribution of each S1P source critical. In this context, S1P source preservation becomes key. Thus, inhibition of platelet S1P release with aspirin impaired recovery from anaphylactic shock in mice. S1P depletion has not been addressed in human anaphylaxis, but was recently reported in septic shock. 19 To appreciate if monitoring and preservation of plasma S1P may provide diagnostic or therapeutic value in circulatory shock, it will be important to address if S1P is also depleted in other severe inflammatory conditions and explore mechanisms of S1P depletion in future studies. The suboptimal engagement of S1P 2 signaling during recovery from systemic anaphylaxis also argues potential therapeutic utility of S1P 2 agonists for maintenance of vascular tone. What Is Known?
• The bioactive lipid sphingosine-1-phosphate (S1P) critically supports vascular development and vascular integrity in mice primarily via the S1P 1 receptor.
• Platelets have been suggested to support vascular integrity after activation of C-type lectin-like receptor 2 by paracrine actions of plateletderived S1P on endothelial S1P 1 .
• S1P deficiency dramatically impairs recovery in mouse models of anaphylactic shock by aggravating loss of vascular integrity and tone.
What New Information Does This Article Contribute?
• Without S1P production, platelet aggregation and spreading is impaired, and platelets lose their capacity to promote endothelial barrier function in vitro.
• Blocking S1P production in platelets, erythrocytes, endothelial cells, or smooth muscle cells does not impair vascular development or integrity, including in conditions where platelet C-type lectin-like receptor 2 is essential, suggesting that redundant S1P sources normally secure these functions in vivo.
• In a mouse model of systemic anaphylaxis, rapid and profound depletion of plasma S1P renders S1P delivery by both platelets and erythrocytes necessary for survival. S1P is critical for vascular development and function, but the relative importance of different cell types for provision of bioactive S1P is unknown. Dynamic endothelial S1P production may relay barrier protection by other mediators; erythrocytes provide the bulk of plasma S1P and may provide essential S1P during vascular development; and platelet S1P release may protect vascular integrity during inflammation and after immunization. However, when S1P production was selectively impaired in each of these cell types, we found them to be largely redundant for vascular development and function. Accordingly, impairing any single cellular source does not bring plasma S1P below levels predicted as receptor-saturating under homeostasis. In a model of systemic anaphylaxis, we observed rapid depletion of plasma S1P to <20% of basal levels. This rendered circulating sources of S1P essential for recovery, and blocking S1P release with aspirin impaired survival. Although S1P supports vascular integrity and vascular tone in this model via S1P 1 and S1P 2 , respectively, only the latter was essential for the survival benefit of S1P in anaphylaxis. Thus, rapid depletion of plasma S1P may contribute to cardiovascular shock during systemic inflammation, suggesting potential diagnostic value in monitoring S1P levels in human disease and therapeutic benefits in preserving S1P signaling.
Platelet and erythrocyte sources of S1P are redundant for vascular development and homeostasis, but both rendered essential after plasma S1P depletion in anaphylactic shock. 1 . The efficiency and specificity of deletion with the Pdgfb-iCreERT allele with our tamoxifen induction protocol was confirmed by analysis vasculature of different organs (retina, brain, heart, lung) in adult mice crossed with reporter alleles activated by Cre excision 2 .
Bone marrow transplantation. Recipient mice were exposed to 6.5 Gy Cesium 137 radiation twice with a 3-4 hour interval. The day after, each mouse received 10 7 bone marrow cells as indicated i.v. under isoflurane anesthesia. Chimeric mice were used >4 weeks after transplantation. Transplantation efficiency was determined to be >95 % in parallel experiments.
Collection of blood, plasma, serum, erythrocytes, platelets and platelet supernatants. Blood was collected from the retro-orbital venous plexus under isoflurane anesthesia with EDTA-coated capillaries for CBC analysis, platelet rich plasma (PRP) or platelet poor plasma (PPP) collection or in uncoated capillaries for serum preparation. Serum was prepared by centrifugation of coagulated whole blood for 10 minutes at 500 g. PPP was prepared for S1P measurements by centrifugation of anticoagulated blood for 10 minutes at 500 g twice. PRP was prepared for platelet isolation by centrifugation of anticoagulated blood for 10 minutes at 80 g after addition of a 1:1 volume of PIPES buffer (20 mM Pipes, 150 mM NaCl, pH 6.5). PRP was then collected into tubes containing 1/1 volume of wash buffer (140 mM NaCl, 10 mM NaHCO3, 2.5 mM KCl, 0.5 mM Na2HPO4, 1.0 mM MgCl2, 6.46 mM trisodium citrate, 0.1 % w/v dextrose, 0.35% Bovine Serum Albumin (BSA; Fraction V), pH 6.5) supplemented with prostaglandin I2 (PGI2, 1µM, Sigma P6188) and apyrase (100 mU/ml, Sigma A6535) and spun 10 minutes at 500G for platelet isolation. Platelets were then resuspended and washed twice in the same buffer. For S1P release, washed platelets were resuspended to 400 k/µl in 200 µl HBSS with 0.35 % lipid free BSA and stimulated with thrombin (30 nM) and convulxin (250 ng/ml) for 30 minutes at 37 °C. Platelets were then spun down for 10 minutes at 500 g and the supernatant analysed by mass spectrometry. For erythrocyte collection, blood was drawn into 25% ACD and spun for 10 minutes at 80g. Preparation of washed, packed erythrocytes for S1P quantification and transfusions was performed as previously described 1 .
LC-MS/MS analysis of sphingoid bases in plasma, serum and platelet supernatants: 200 μL of plasma, serum, or 200 μL of platelet supernatant, 100 μL of an internal standard solution containing 0.1 μg/mL C17-SPH and 0.1 μg/mL C17-S1P and 1 mL of methanol were mixed, vortexed and centrifuged at 12,000 g for 5 min. Supernatants were transferred into glass vials prior to injection (4 μL) into the UPLC-MS/MS system for analysis, with the autosampler set at 4°C. The UPLC-MS/MS consisted of a Waters Acquity and a Triple QuaDripole (TQD) tandem mass spectrometer. Chromatographic separation was obtained using an Acquity UPLC HSS T3 column (100mm L×2.1mm i.d., 1.7 μm particle size, Waters, Milford, MA, USA) with a guard column of the same material maintained at 65°C. The mobile phase consisted of water containing 30 mM ammonium acetate and formic acid 0.1% (eluent A) and methanol (eluent B) at a flow rate of 0.5 mL/min in a gradient mode. The following linear elution gradient was used: 0-0.2 min, 100% A; 0.2-0.7 min, 100% to 10% A; 0.7-1.3 min, 10%A/90%B; 1.3-1.6 min, 10% to 100% A. Between runs the system was re-equilibrated with 100% eluent A for 3.4 min. The mass spectrometer was operated in the positive ion mode with an electrospray voltage of 3600V. Sphingoid bases were quantified using multiple reaction monitoring (MRM) and peak areas were integrated with Waters QuanLynx software.
HPLC quantification of S1P concentrations in platelets and erythrocytes: Methanol (1 ml) containing 2.5 μl concentrated HCl was added to washed platelets or erythrocytes in 50 μL PBS. C17-S1P (15 pmoL) was added as internal standard and lipids were extracted by addition of 1 ml chloroform, 200 μl NaCl (4 M) and 100 μl NaOH (3 M). The alkaline aqueous S1P-containing phase devoid of other sphingoid bases and of the majority of hydrophobic PL was transferred to a clean tube and the organic phase re-extracted with 0.5 ml methanol, 0.5 ml of 1M NaCl and 3N NaOH (50 μl). The alkaline aqueous phases were combined, acidified with 100 μl concentrated HCl and extracted twice with 1.5 ml chloroform. The organic phases were evaporated and the dried lipids were dissolved in a mixture (50 μl Calcium signaling. Washed platelets were loaded with fura-2 AM (4 µM) in HBSS supplemented with PGI2 (1 µM), Apyrase (100 mU/ml) and EDTA (1 mM) for 40 minutes at 37 °C, spun down and resuspended to 100 k/uL in calcium-free HBSS supplemented with 10 mM HEPES and 100 µM EGTA. 100 µL aliquots of loaded platelets were assayed per well in 96-well black-walled clear-bottomed plates using a FlexStation (Molecular Devices) plate reader warmed at 37°C. Fluorescence emission at 510 nm after alternating 340 nm and 380 nm excitation wavelengths was monitored every 3.5 seconds for 5 minutes. Human α-thrombin (10 nM) or vehicle control was added with a robotic injector after establishment of baseline emission ratio. Results were analysed using SoftMax Pro software. Fluorescence ratio (340/380 nm) was normalized to basal fluorescence ratio for each well, and maximal responses and area under the curve (AUC) determined for each sample. Each sample was from an independent mouse.
Platelet preparation for aggregation and secretion. Blood was collected into ACD-C solution (13 mM citric acid, 12.6 mM sodium citrate, 11mM D-glucose) by cardiac puncture. To optimize the yield of platelet recovery, blood was diluted 2:1 with wash buffer (36mM citric acid, 5 mM D-glucose, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 103 mM NaCl, pH = 6.5 in presence of 0.1 U/mL apyrase and 10 μM PGE1). Diluted platelet-rich plasma (PRP) was obtained by centrifugation at 170 g for 7 min, diluted in wash buffer (1:1) with inhibitors (as above) and centrifuged 10 min at 750 g. The platelet pellet was resuspended in wash buffer and centrifuged as above. Finally, the platelets were resuspended to 3.5x10 8 /mL in HEPES buffer (10 mM HEPES, 140 mM NaCl, 3 mM KCl, 5 mM NaHCO3, 0,5 mM MgCl2, 10 mM D-glucose, pH = 7.35), counted using a veterinary counter MS9 (MS Laboratoires) added 2 mM calcium chloride depending of the experiment to be performed. Platelet aggregation. Platelet aggregation was measured using a Biodata aggregometer (Biodata, PAP-8E). Washed platelets (3.5.10 8 /mL) were pre-incubated for 2 minutes at 37°C. Platelet aggregation was then induced by addition of collagen (0.75 µg/ml) or ADP (1.5 µM). For ADP-induced aggregation, fibrinogen (5 µg/mL) was added just prior to pre-incubation. Aggregation was registered as change in light transmission and was calculated as the maximum of aggregation curve (% aggregation) and the area under the aggregation curve (AUC).
Platelet spreading assessed by scanning electron microscopy (SEM). Washed platelets (3x10 8 /mL) were dropped on glass slides coated with either 2% BSA (resting conditions) or fibrinogen (0.2 mg/mL). After 30 minutes of adhesion, a drop of fixation solution (0.1 M sodium cacodylate, 2 mM CaCl 2 , 2% PFA, 4% glutaraldehyde) was added, and the slides incubated overnight in a bath of 0.1 M sodium cacodylate/2 mM CaCl 2 . The day after, samples were fixed with 1% osmium tetroxide, washed and dehydrated with an ethanol series (25 %, 50 %, 75%, 95%, 100%) and dried by HMDS. Samples were then gold coated with a JEOL JFC-1300 Auto fine coater (JEOL Europe SAS, Croissy Sur Seine, France) and examined with a JEOL JSM-6510 LV.
Tail bleeding times. A 3 mm transection was performed of the tail of mice anesthetized with ketamine 50 mg/kg (Clorketam 1000®, Vétoquinol S.A, Magny-Vernois, France) and xylazine 6 mg/kg (Rompun®, Bayer Santé, Puteaux, France). The tail was immediately immersed in 10 ml of 0.9% isotonic saline at 37°C, and the time to permanent cessation of bleeding recorded. Tail bleeding was monitored for at least 90 seconds beyond this time point, to ensure that bleeding did not re-start. Developmental and perinatal bleeding. Spontaneous developmental and perinatal hemorrhage was addressed in Sphk deficient and, for comparison, platelet deficient (Nfe2 -/-) embryos and neonates. Embryos were harvested 12.5 or 14.5 days after conception (E), grossly inspected for cerebral hemorrhage, evidence for blood in lymphatic structures and other abnormalities in a blinded manner, and genotyped. Neonates (p1-p3) were anesthetized with ketamine/xylazine (100 and 10 mg/kg, respectively) and transcardially perfused with saline before harvesting the brain and scoring for hemorrhage in a blinded manner.
Irradiation-induced bleeding. 5-8 week old C57BL/6 males were exposed to 6.5 Gy Cesium 137 radiation twice with a 4 hour interval. The day after, each mouse received 5x10 6 E14.5 fetal liver cells (Nfe2 -/-or Nfe2 +/+ ) or 10 7 bone marrow cells (Sphk deficient or littermate control donors) i.v. under isoflurane anesthesia. 10 or 13 days (as indicated) after irradiation, mice were anesthetized with ketamine/xylazine (80-100 and 5-10 mg/kg, respectively), and transcardially perfused with 1 % PFA after collection of blood for determination of platelet numbers. Brain were then harvested and photographed, and the number of bleeding spots quantified by an examiner blinded to genotype. Reverse passive Arthus reaction (detailed description). Shaved mice were anesthetized with ketamine/xylazine (100 and 10 mg/kg, respectively) and the reverse passive Arthus reaction (rpA) reaction elicited by s.c. injection of anti-BSA IgG (60 µg in 20 µL saline) immediately followed by i.v. injection of BSA (50 µg/g) in saline. Mice were sacrificed 4 hours later and biopsies of control and inflamed skin harvested with 5 mm diameter biopsy punches. Skin biopsies were then weighed, homogenized and sonicated in cold PBS. Tissue lysates were centrifuged and a 30 µL aliquot of each supernatant was collected for measurement of hemoglobin content by addition of formic acid and absorbance reading at 405 nm. Pelleted tissue lysates were then resuspended and diluted 1:1 (vol:vol) with potassium phosphate buffer (50 mM final) supplemented with hexadecyltrimethylammonium bromide (HTAB, 0.9 % final, Sigma, St. Louis, MO) to extract myeloperoxidase (MPO). After 5 minute centrifugation at 10000 g, MPO activity was measured in supernatants by adding 3,3′,5,5′-Tetramethylbenzidine (TMB, Sigma). The reaction was stopped with sulfuric acid and the absorbance at 450 nm was recorded using a Multiskan plate reader (Thermo Labsystems Nepean Ontario Canada).
Pneumonia (detailed description).
Mice were anesthetized with ketamine/xyalzine (100 mg/kg, 10 mg/kg, respectively) and inoculated intranasally with 25 µg Pseudomonas aeruginosa LPS prepared in a final volume of 20 µL PBS (10 µL/nostril). 6 hours later, the trachea was canulated with an 18-gauge angiocath, and bronchoalveolar lavage (BAL) performed 3 times with 0.6 mL sterile PBS. Hemoglobin content was determined by absorbance reading at 405 nm and blood cells in BAL quantified using a HemaVet cell analyzer (Drew Scientific).
Immunization and analysis of HEV bleeding (detailed description).
Mice received an injection of 20 µL of an emulsion of complete Freunds adjuvant/Ovalbumin PBS in the right hock and 20 µL PBS in the contralateral hock under isoflurane anesthesia as described by Herzog et al. 3 . Where indicated, mice were given 350 μl washed, packed erythrocytes from Sphk1 f/f :2 -/-donors on day 4 and 6 after immunization or depleted of platelets by injection of 2 µg/g of anti-GP1bα or rat IgG control (Emphret Analytics, Eibelstadt, Germany) on day 6 after immunization by retro-orbital injection. Blood was drawn in EDTA immediately prior to transcardial perfusion to confirm antibody-induced thrombocytopenia. On day 7 after immunization, mice were anesthetized and transcardially perfused with 1% PFA to remove intravascular blood. Right and left popliteal and inguinal LNs were dissected and photographed. Bleeding on the efferent side was scored in a blinded fashion on a scale from 0-5, where 0 represents no bleeding and 5 represents strong bleeding. When bleeding was observed in the popliteal lymph nodes, mesenteric, para-aortic and axial LNs were also inspected for signs of bleeding. Strong bleeding in the ipsilateral popliteal lymph node, observed with platelet depletion and in plasma S1Pless mice, was sometimes associated with bleeding also in ipsilateral inguinal, contralateral popliteal and para-aortic lymph nodes, but not in axial or contralateral inguinal lymph nodes.
Anaphylactic shock modeled with PAF injection. Passive systemic anaphylaxis was mimicked by i.v. injection of platelet activating factor (PAF) at indicated concentrations 4, 5 . Mice were anesthetized with isoflurane (2%) and PAF administered via the retro-orbital venous plexus. Where indicated, 3-4 drops of blood were collected into EDTA coated capillaries from the contralateral retro-orbital plexus 10 minutes after injection for CBC analysis (HemaVet, Drew Scientific). Behavior and survival were followed for 60 minutes, after which all surviving animals were euthanized. Mice displaying spasms and loss of righting reflex were euthanized before this endpoint and counted as non-survivors. Aspirin (100 mg/kg), ibuprofen (40 mg/kg) or vehicle was administered i.p. 1 hour prior to PAF injection where indicated.
Intravital microscopy. Wild-type C57/BL6J mice were anesthetized with ketamine/xylazine (100 mg/kg, 10 mg/kg, respectively), and the mesentery was carefully exposed and spread on a Petri dish via a midline laparotomy incision. For staining of circulating platelets and leukocytes, mice were injected with rhodamine-6G (3 mg/kg mouse) through the retro-orbital venous sinus, and placed under an upright fluorescence macroscope (MacroFluo, Leica Microsystems, Nanterre, France) equipped with a thermostated heating plate and a 5X objective, and connected to a sCMOS camera (Orca-Flash-4.0, Hamamatsu Photonics, Hamamatsu, Japan) for image acquisition using Metamorph software (Molecular Devices, Downington, PA). After 10 min during which baseline cell interactions in arteries and veins were recorded, PAF (4 µg/kg mouse) was injected through the retro-orbital venous sinus and cell interactions were followed for up to 30 min.
Echocardiography and ultrasound pulsed Doppler blood flow recordings. Before and 30 minutes after i.v. injection of PAF (4 µg/kg), mice were anesthetized with isoflurane (0.5%), placed on a heating mat and subjected to ultrasound measurements using an echocardiograph (Acuson S 3000, Siemens, Erlangen, Germany) equipped with a 14-MHz linear transducer (14L5 SP). Heart rate and left ventricle and pulmonary artery internal diameters were measured as well as peak systolic, end-diastolic, and timeaveraged mean blood flow velocities in the pulmonary artery for cardiac output calculation, and in the right renal artery and basilar trunk for renal and brain perfusion as previously described [6] [7] [8] .
Blood pressure and heart rate monitoring. Acute pressor responses were measured in mice anesthetized with sodium pentobarbital (60 mg/kg i.p.). Flexible plastic catheters were introduced into the left carotid artery and jugular vein. The arterial catheter was connected to a pressure transducer (SS13L) and a Biopac System MP35. The MP35 unit converts incoming signals into digital signals that were processed using an algorithm based on feature extraction to detect and measure the characteristic of BP cycle, BSL 4.0 (Biopac Systems, Inc.). A syringe was introduced into the venous catheter and used for bolus injection of PAF (2 μg/kg) after an initial stabilization period of >30 minutes. Blood pressure and heart rate were then recorded for 60 minutes. Online Figure IV . Effect of S1P signaling deficiencies on blood pressure and heart rate after PAF challenge. Mice lacking S1P production in all cells that provide S1P to plasma (Sphk1 f/-:2 f/-:Mx1Cre + ; A), S1P 2 in all cells (S1pr2 -/-; B), S1P production selectively in megakaryocytes/platelets (Sphk1 f/-:2 f/-:Pf4Cre + ; C) or S1P production selectively in erythrocytes (Sphk1 f/-:2 f/-:EporCre + ; D), and their respective littermate controls were challenged with PAF (2 μg/kg) under pentobarbital anesthesia and blood pressure and heart rate monitored for 60 minutes and normalized to pre-stimulation values. Asterisk indicates the death of an animal. SBP, systolic blood pressure; DBP, diastolic blood pressure. SBP and HR for A and B are shown in Figure 8B . Mean +/-SEM is shown. Two-way ANOVA did not reveal statistically significant differences between genotypes for any group.
Online Figure V. Echocardiography and ultrasound pulsed Doppler blood flow analysis before and after PAF treatment. Example of parameters assessed before and after i.v. injection of PAF (4 μg/kg) in "Plasma S1Pless" (Sphk1 -/-) were excluded. Note that mice with severe circulatory shock at 30 minutes that survived showed almost complete functional recovery at 2 hours. Measurements were performed on a Siemens Acuson S 3000 (Erlangen, Germany) equipped with a 14-MHz linear transducer (14L5 SP).
Online Videos
PAF-induced anaphylactic shock causes interactions between platelets, leukocytes, and the vessel wall in both arteries and veins. Intravital microscopy imaging of interactions between platelets, leukocytes, and the vessel wall before and 20 minutes after PAF-induced anaphylaxis. Five second timelapse microscopy videos taken in arteries (Online Video I) and veins (Online Video II) before (left panels) and 20 minutes after (right panels) PAF (4 μg/kg) injection, as indicated. PAF injection led to transient interactions between platelets, leukocytes and the vessel wall in both arteries and veins, as well as to firm adhesion (≥ 5 sec). White and black arrows indicate firmly adherent platelets and leukocytes, respectively. Erythrocytes, which do not bind rhodamine-6G, can also be observed as black spheres adhering firmly to the venular wall 20 minutes after PAF injection. Videos are representative of observations made in 6 wild-type mice. 
